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We previously showed that certain tyrphostin derivatives, known as protein tyrosine kinase inhibitors, also act as
topoisomerase I-specific antagonists and inhibit Moloney murine leukemia virus replication in vitro in acutely and chronically
infected cells. However, an accurate portrayal of retroviral-induced disease cannot rely exclusively on extrapolations from
in vitro data. Therefore, experiments with animal models are essential for evaluating the efficacy of a specific drug in vivo.
In this study, we examined the effect of tyrphostin AG-1387 on murine AIDS (MAIDS) development in C57BL/6J mice injected
with the LP-BM5 virus mixture. A single dose of tyrphostin, administered together with or 24 h post virus inoculation,
decreased the development of MAIDS symptoms as measured by spleen and lymph node weight, the T-cell response to
concanavalin A (con A), and spleen architecture. Furthermore, weekly treatment with tyrphostins totally abolished MAIDS
symptoms and prevented the viral infection of the spleen cells as measured by the absence of viral RNA and the restoration
of T-cell function in these spleens. These results implicate that prolonged treatment with tyrphostins is needed for the
prevention of MAIDS development in infected mice and suggest that it may be applied as a legitimate remedy for the
treatment of retroviral-induced diseases. © 2000 Academic Press
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The clinical importance of retroviruses as the caus-
ative agent of severe disease in humans and animals
has led to extensive research aimed at developing spe-
cific antiretroviral drugs.
Tyrphostins are synthetic compounds that are potent
and selective protein tyrosine kinase (PTKs) inhibitors.
They can serve as antiproliferative agents and molecular
tools to investigate signal transduction pathways of PTKs
(Levitzki, 1992; Levitzki and Gazit, 1995). In recent stud-
ies, we showed that certain tyrphostin derivatives inhibit
topoisomerase I (topo I) activity in vitro by preventing the
binding of the enzyme to the DNA, a mechanism which
differs from that described for camptothecin (CPT), a
known topo I antagonist (Aflalo et al., 1994).
We previously showed that topo I activity is associated
with retroviral particles, probably responsible for induc-
tion of the topological changes required for integration
and expression of the viral genome (Matsrafi et al., 1996;
Priel et al., 1990; Weis and Faras, 1981). In addition, it was
shown that topo I antagonists, such as CPT and its
derivatives, inhibit retroviral replication in acute and
chronically infected cells (Li et al., 1994; Priel et al.,
991a,b). Moreover, the efficacy of this drug as an inhib-
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95tor of retroviral-induced diseases (i.e., T-lymphoma
aused by Moloney murine leukemia virus [Mo-MuLV];
rythroleukemia induced by spleen focus forming virus)
n mice was also demonstrated (Priel et al., 1993). These
eports suggest that topo I inhibitors may serve as anti-
etroviral drugs. Since camptothecin and its derivatives
xerted their cytotoxic effects by introducing single-
trand DNA breaks and showed toxic side effects in
linical trails (Gerrits et al., 1997; Wang et al., 1997), it
was important to evaluate the antiretroviral effect of other
topoisomerase antagonists, such as tyrphostin deriva-
tives, that inhibited topo activity by a different mode of
action.
In our previous studies, we showed that AG-555, a
tyrphostin derivative, inhibited the replication of Mo-
MuLV in vitro in acute and chronically infected cells. This
drug prevented the integration of the viral DNA into the
host genome in acutely infected cells and reduced the
level of viral RNA and proteins in Mo-MuLV chronically
infected cells (Aflalo et al., 1994; Seri et al., 1997).
To evaluate the efficacy of tyrphostins as antiretroviral
drugs in vivo, we examined their effect on the develop-
ment of murine AIDS (MAIDS) in mice. MAIDS is a severe
disease that is induced in C57BL/6 mice by infection with
the Duplan strain of murine leukemia virus (MuLV) (Aziz
et al., 1989). Infected mice exhibit a syndrome with fea-
tures that are pathologically similar to the human immu-
nodeficiency virus (HIV) infection, including lymphade-
nopathy, splenomegaly, hypergammaglobulinemia, T-
and B-cell dysfunctions, late appearance of B-cell lym-
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96 SKLAN, GAZIT, AND PRIELphomas, and opportunistic infections (Morse et al., 1989,
1992; Mosier et al., 1985).
In this study we have shown that long-term treatment
with the tyrphostin derivative AG-1387 can prevent the
onset of MAIDS in C57BL/6J mice.
RESULTS
The effect of different tyrphostin derivatives on LP-
BM5 virus mixture in BM5 chronically and SC-1
acutely infected cells
Before examining the effect of tyrphostin derivatives in
vivo on MAIDS development, we determined the effect of
the tyrphostin AG-1387 in vitro on the replication of LP-
BM5 mixture of MuLV viruses (ecotropic, recombinant
mink cell cytopathic focus-inducing and replication-neg-
ative defective viruses) that induce MAIDS in mice. We
used the BM5 cells, which are SC-1 mouse embryo
fibroblasts chronically infected with the LP-BM5 mixture
of MuLV viruses. Cell viability in the presence of increas-
ing concentrations of tyrphostins was examined by the
trypan blue exclusion assay, and the CC50 for AG-1387
was 100 mM. Therefore, we examined the effect of AG-
1387 on MAIDS replication using noncytotoxic doses of
this compound (1–50 mM).
FIG. 1. Effect of AG-1387 on viral protein synthesis determined in LP
BM5 cells (106/flask) were treated for 48 h with increasing concentratio
mg protein was separated by electrophoresis on a 10% polyacrylamid
antibodies (upper panel). Anti-b-actin served as a control (lower panel
wo different experiments (graph). (B) SC-1 (5 3 105) cells were incuba
P-BM5 virus in the presence (lane 3) or the absence (lane 2) of 10 mM A
7 days postinfection (I) and the virus was collected from the culture m
estern blot analysis using anti-MuLV p30 antibodies.To measure the influence of tyrphostin treatment on
the replication of MAIDS virus in vitro we performed thefollowing experiments: (1) the effect of tyrphostin treat-
ment on MAIDS virus replication in LP-BM5 chronically
infected cells and (2) the effect of this compound on SC-1
cells acutely infected with the LP-BM5 virus mixture.
Two criteria were examined: the level of the virus
particles released to the cell culture media and the level
of the MAIDS-specific gag precursor (pr60gag). In the
LP-BM5 chronically infected cells the effect of tyr-
phostins on the level of virus particles released to the
cell culture media was examined by measuring RT ac-
tivity in pelleted virus from the culture media of tyrphos-
tin-treated (1–10 mM) and untreated cells 48 h after
treatment. A dose-dependent inhibition of RT activity was
observed and the most effective viral inhibition (88%) was
detected at 10 mM of tyrphostin. This tyrphostin concen-
tration was 10-fold lower than the dose required for
cytotoxic effects. By measuring the RT activity in the
culture media we examined the effect of tyrphostin only
on the MuLV helper viruses and not on the defective
MAIDS virus. Therefore, we investigated the effect of
tyrphostin treatment on the level of viral proteins in the
BM5 chronically infected cells. The reduction in viral
replication, following 48 h of AG-1387 treatment, was
confirmed by Western blot analysis of the viral antigens
produced in chronically infected BM5 cells.
hronically infected cells (A) and in SC-1 acutely infected cells (B). (A)
0 mM, lanes 1–5) of AG-1387. Cells were lysed in RIPA buffer and 200
Proteins were detected after immunoblotting by anti-p15 viral protein
itometric analysis was performed and the results are means 6 SD of
the presence of Polybrene (8 mg/ml) for 24 h. Cells were infected with
. Lane 1, uninfected SC-1 cells. Cellular protein extracts were prepared
(II). Cellular proteins (150 mg) and total virus lysate were analyzed by-BM5 c
ns (0–5
e gel.
). Dens
ted in
G-1387Figure 1A shows a significant decrease (40–60%) in
the amount of pr65gag, the helper MuLV virus gag precur-
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97MAIDS INHIBITION BY TYRPHOSTIN DERIVATIVEsor protein, and pr60gag, the specific MAIDS gag protein
(Huang et al., 1995) when the cells were treated with
10–50 mM of tyrphostins. In addition a gag-related pro-
tein intermediate of 40 kDa, which is a cleavage product
of the pr60gag (Huang and Jolicoeur, 1990) was detected
in the chronically infected cells and was significantly
reduced following tyrphostin treatment. This reduction
was specific to the viral proteins, since no change in the
amount of the cellular b-actin was observed (Fig. 1A).
The effect of AG-1387 on the infection of SC-1 cells
with the LP-BM5 MuLV virus mixture was determined by
measuring the level of viral particles in the culture media
and the level of viral proteins in the infected cells. Tyr-
phostin was added during the infectious process and the
virus particles were pelleted from the culture medium 7
days postinfection. In parallel, the cellular proteins were
extracted and viral proteins were detected by Western
blot analysis using specific anti-MuLV-p15 antibodies.
The results depicted in Fig. 1B (top panel) show that, in
addition to the pr65gag, the pr60gag MAIDS-specific protein
as detected in the SC-1-infected cells (lane 2), although
hese proteins were not observed in the tyrphostin-
reated cells (lane 3). Moreover, virus particles were
resent in the culture media of the SC-1-infected cells as
easured by the presence of the p30 viral protein (Fig.
B, bottom panel, lane 2). But, in the tyrphostin-treated
ells no viral antigens could be detected in the culture
edium of the SC-1-infected cells (Fig. 1B, bottom panel,
ane 3). These results suggest that AG-1387 prevented
he infection of SC-1 cells by the LP-BM5 MuLV virus
ixture.
he effect of AG-1387 on MAIDS-induced disease in
oung adult C57BL/6J mice
The present results together with our previous pub-
ished data (Aflalo et al., 1994) suggest that tyrphostins
an act as antiviral drugs at noncytotoxic doses in
itro. To evaluate the efficacy of this drug in vivo
57BL/6J mice were injected with 0.2 ml of the culture
upernatant of BM5 cells containing the LP-BM5 virus
ixture (103 plaque-forming units [PFU]/ml). Spleens
ere palpated weekly for signs of enlargement and
he mice were terminated 10 months after virus injec-
ion. Mice were divided into six different groups (each
ontaining 10 mice) as follows: control uninfected
ice (Group 1), control uninfected mice injected with a
eekly dose of tyrphostin (Group 2), mice infected with
he MAIDS virus (Group 3), infected mice treated with
single dose of tyrphostin administered immediately
fter virus inoculation (Group 4), infected mice treated
ith a single dose of tyrphostin administered 24 h
fter virus inoculation (Group 5), and infected mice
reated weekly with tyrphostin starting 24 h after virus
noculation (Group 6). MAIDS development was mon-
tored by examining: (1) the weight of spleen and
t
uymph nodes; (2) the response of spleen cells to mi-
ogens; (3) the presence of viral RNA in the spleen
ells; and (4) histopathologic examination of the
pleens.
he effect of tyrphostin treatment on the
evelopment of splenomegaly and lymphadenopathy
The results depicted in Fig. 2 show that 10/10 mice that
ere injected with the virus developed severe spleno-
egaly (column 3); the spleen weight varied from 0.3 to
.6 mg and mouse body weight ranged between 22 and
6 g. Therefore the results are presented as the ratio
etween the spleen weight and the mouse body weight.
igure 2 shows a decrease (1.5- to twofold) in spleno-
egaly in infected mice that were treated with a single
ose of tyrphostin given together or 24 h after virus
nfection (compare columns 4 and 5, respectively, to
olumn 3). However, the weekly treatment of infected
ice abolished splenomegaly completely (compare col-
mn 6 to 3) and the average spleen weight of these mice
as identical to that of the control mice (column 1). It
hould be noted that tyrphostin treatment alone did not
ffect spleen weight (column 2) and no visible side ef-
ects were observed. Similar results were obtained when
esenteric lymph nodes were removed from the differ-
nt treatment groups. Infected as opposed to uninfected
ice showed a 2.5-fold increase in lymph node weight.
eekly tyrphostin treatment prevented the enlargement
f the lymph nodes. A single tyrphostin dose adminis-
ered immediately or 24 h post virus inoculation de-
reased lymphadenopathy by 50%. Weekly tyrphostin
FIG. 2. The effect of tyrphostin treatment on the development of
splenomegaly. Mice were terminated 10 months after virus infection
and the spleens were removed and weighed. The ratio between spleen
weight and body weight was calculated. The results are means 6 SD
f two experiments, which contained 10 mice in each group.reatment did not affect the weight of the lymph node in
ninfected mice.
98 SKLAN, GAZIT, AND PRIELThe effect of tyrphostin treatment on the response of
spleen cells from infected mice to concanavalin A
(Con A)
As was previously shown (Aziz et al., 1989; Legrand et
al., 1981; Mosier et al., 1985) we observed a severe
decline in the response of spleen cells to Con A in mice
infected with the virus (Fig. 3, column 3). Tyrphostin
treatment administered as a single dose together or 24 h
post virus inoculation restored 60–70% of the spleen cell
response to Con A (compare columns 4 and 5 to 1 and 2).
The full restoration of the spleen cells’ response to Con
A was observed in infected mice treated with a weekly
dose of tyrphostins (column 6).
The effect of tyrphostin treatment on viral RNA
presence in spleens from infected mice
Total RNA was extracted from spleen cells derived
from the different treatment groups and analyzed for the
presence of viral RNA by Northern blot using the D30
probe, which recognizes only the defective MAIDS virus
genome (Huang et al., 1989, 1992). Five spleens from
each treatment group were separately analyzed and,
since similar results were obtained, Fig. 4 represents the
analysis of one spleen from each treatment group. The
results demonstrated in Fig. 4 (lane 2) clearly show that
the 4.2-kb MAIDS viral RNA was present in the spleens
of infected mice (Group 3) but was not detected (lane 4)
in the spleens of infected mice treated weekly with tyr-
phostins (Group 6). Under our experimental conditions
the viral RNA was not observed in the infected mice
treated with a single dose of tyrphostin administered
FIG. 3. The response of spleen cells to Con A. Spleen cells (5 3
105/well) were incubated with Con A (1 mg/ml) for 72 h and cell
proliferation was determined by [3H]thymidine (1 mCi/well) incorpora-
tion. The results are means 6 SD of four experiments.immediately after virus inoculation (Group 4) or in the
infected mice treated with a single dose of tyrphostinadministered 24 h after virus inoculation (Group 5). How-
ever, overexposure of the nitrocellulose membrane re-
vealed a very faint RNA band in the spleens of Groups 4
and 5 (data not shown). Tyrphostin treatment did not
affect the level of the cellular glyceraldhyde-phospho-
dehydrogenase (GAPDH) RNA (Fig. 4, bottom panel).
These results are compatible with the data described
in Figs. 2 and 3, indicating that only a weekly treatment
of tyrphostin totally abolished viral infection.
Histopathologic examination
Histopathologic examination was performed on
spleens derived from the different mice treatment
groups. Spleens from the control uninfected mice (Fig.
5A) and control uninfected mice treated with tyrphostins
(not shown) showed the normal architecture of the
spleen by indicating clear distinctions between the red
and white pulp and clear identification of germinal cen-
ters and the central artery. In contrast, spleens derived
from viral-infected mice (Figs. 5B and 5C) clearly dem-
onstrated the destruction of the normal architecture of
the spleen; that is, the red and white pulp were not
distinguishable, a large amount of immunoblast and
plasmacytoid cells were observed, and erythropoetic tis-
sue impinged on the central artery. In addition, clumps of
myeloid and erythropoetic tissue were observed in a
poorly differentiated stage. In contrast, spleen architec-
ture from the infected mice treated weekly with tyr-
phostins was normal (Fig. 5D).
DISCUSSION
In this study we demonstrated, for the first time, that
certain tyrphostin derivatives that inhibit both topoisom-
FIG. 4. Examination of the presence of viral RNA in spleen cells from
infected mice. Viral RNA was prepared from the spleen cells of infected
mice (lane 2) and from infected mice treated with a single dose of
AG-1387 (lane 3) or mice treated weekly with tyrphostin (lane 4). Lane
1, untreated mice. Northern blot analysis was performed using the D30
probe. Bottom panel: the membrane was probed with GAPDH probe as
control.
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99MAIDS INHIBITION BY TYRPHOSTIN DERIVATIVEerases and PTKs reduced or totally abolished the devel-
opment of MAIDS in mice. The prevention or the reduc-
tion in the development of this disease depended on the
dose and time of tyrphostin treatment. A single dose of
tyrphostin administered together with virus inoculation
reduced, but did not abolish, the MAIDS symptoms as
measured by the different established parameters (Aziz
et al., 1989; Jolicoeur, 1991; Simard and Jolicoeur, 1991).
Only weekly treatments with tyrphostins totally prevented
the development of MAIDS in the infected mice, suggest-
ing that prolonged treatment with this drug is needed to
totally prevent the onset of this disease. The LP-BM5
MuLV virus mixture used for the infection of the C57BL/6J
mice also contained the MuLV helper viruses in addition
to the defective MAIDS virus. In previous studies, we
showed that tyrphostins inhibited Mo-MuLV replication
in vitro and affected the early (viral DNA integration) and
late (viral RNA and protein synthesis) stages in the viral
life cycle (Seri et al., 1997).
In this study, we showed that tyrphostin treatment also
inhibited the synthesis of the pr60gag MAIDS-specific
rotein, suggesting that this drug inhibits both the Mo-
FIG. 5. The effect of AG-1387 treatment on the development of MAIDS
the control uninfected mice (A), viral-infected mice (B and C), and infect
Formalin, stained with hematoxylin and eosin, and examined by light m
are: red pulp (1), white pulp (2), central artery (CA), myeloid and erythuLV and MAIDS protein synthesis. It was shown that
elper-free stocks of the defective Duplan virus inducedAIDS in mice (Huang et al., 1989); therefore, inhibition
of the replication of the helper viruses only should not
prevent the development of MAIDS. Thus, our in vitro
data together with the in vivo results suggest that tyr-
phostin treatment inhibits the development of MAIDS by
affecting both the MAIDS and helper viruses.
The mechanism by which this drug affects viral repli-
cation in vitro and MAIDS development in vivo is still
unclear. Several possibilities based on the biochemical
properties of this drug can be considered:
1. The drug affects viral replication by a direct influ-
ence of the viral life cycle, such as inhibition of the
proviral DNA synthesis or the viral DNA integration pro-
cesses as previously demonstrated for Mo-MuLV (Seri et
al., 1997). It may also specifically affect the viral RNA and
protein synthesis (Seri et al., 1997). Our finding that the
MAIDS viral RNA was not detected in the spleens of
infected mice treated with tyrphostins suggests that tyr-
phostins may prevent the integration of the proviral DNA
and/or the viral RNA synthesis in vivo.
2. Tyrphostin may specifically affect the functions of
rmined by histopathological examination. Spleens were removed from
e treated weekly with tyrphostins (D). The spleens were fixed with 10%
opy (A, B, D: 3120; C: 3300). The numbers and letters in the pictures
lonies (ME), megakaryocytes (M).as dete
ed micviral proteins. Previous studies have shown that the p15
matrix protein of Mo-MuLV is a phosphotyrosine protein
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100 SKLAN, GAZIT, AND PRIEL(Seri and Priel, 1996), and tyrosine-phosphorylated HIV
matrix protein regulates the transport of the viral prein-
tegration complex to the host nucleus (Gallay et al.,
1995). Therefore, it is possible that tyrphostin inhibits the
phosphorylation of the matrix protein and affects viral
replication. In addition, the effect of tyrphostins on spe-
cific viral proteins such as the HIV integrase (Mazumder
et al., 1995) may also explain its antiviral properties.
3. Since tyrphostins are known as PTK antagonists
(Levitzki, 1992; Levitzki and Gazit, 1995) they may affect
viral replication indirectly by influencing various cellular
parameters such as signal transduction mediated by
PTK. It was shown that tyrphostins inhibited specific
PTKs that modify the RNA polymerase II by phosphory-
lation and thus may inhibit the transcription of cellular
and viral genes (Yura et al., 1995).
4. The above-suggested mechanisms could explain
the effect of tyrphostin on retroviral replication in vitro,
but the mode of action by which tyrphostins affect MAIDS
development in vivo might differ. The infection of target
cells is the first event to occur following virus injection.
However, since expansion of this target cell population
occurs early following infection and in large scale, it is
proposed that proliferation of these target cells consti-
tutes the primary and critical event in the disease (Huang
et al., 1989). Therefore, it is possible that, in addition to
the antiviral activity of tyrphostin, this compound inhibits
MAIDS development as a result of its antiproliferative
effect in vivo (Levitzki, 1992).
5. The correlation between the ability of a drug to
inhibit topo I and its antiviral activity has not yet been
substantiated. However, since it was shown that topo I
antagonists are effective antiretroviral drugs in vitro (Li et
al., 1994; Priel et al., 1991a,b) and in vivo (Priel et al.,
1993), it is possible that AG-1387 (potent topo I inhibitor)
also exerts its antiviral activity as a result of its ability to
inhibit topo I.
In conclusion, tyrphostin AG-1387 prevented and in-
hibited MAIDS development by affecting both viral
and/or cellular targets. A prolonged treatment with tyr-
phostin inhibited MAIDS development without causing
any apparent toxic side effects, suggesting its applica-
tion as a legitimate remedy for the treatment of retroviral-
induced diseases.
MATERIALS AND METHODS
Cells
BM5 cells, which are SC-1 mouse embryo fibroblasts
chronically infected with LP-BM5 virus mixture (Yetter et
al., 1988), or uninfected SC-1 cells were grown in Dul-
becco’s modified Eagle’s medium supplemented with
10% fetal calf serum, 1% penicillin-streptomycin, and 1%
L-glutamine.ompounds
Tyrphostin derivative AG-1387 was synthesized by Dr.
. Gazit (Hebrew University in Jerusalem). Stock solu-
ions of the drug were prepared in 100% dimethyl sulfox-
de (DMSO) and stored at 270°C.
irus preparation
Cells were grown as described above and the virus
as harvested from the culture medium every 3 to 4
ays. The medium was first centrifuged for 6 min (1400
pm) to eliminate cell debris, after which viral particles
ere then isolated by further ultracentrifugation for 2.5 h
t 25,000 rpm. The concentrated virus was resuspended
n TE (10 mM Tris–HCl, pH 8, 1 mM EDTA) and stored
rozen at 270°C. Virus titer was determined by estab-
ished techniques (Hartley and Rowe, 1975; Hartley et al.,
977).
yrphostin cytotoxicity
To determine the cytotoxicity of the examined tyrphos-
in derivatives, SC-1 uninfected cells and BM5 chroni-
ally infected cells were cultivated at 105 cells/well in
24-well Costar dishes (Costar, Cambridge, MA). Follow-
ing overnight incubation, fresh media containing in-
creased drug concentrations were added for 48 h. Equiv-
alent volumes of DMSO were administered to untreated
control cells. Following incubation, all cells were washed
and resuspended in fresh medium. Cell viability was
determined by the trypan blue exclusion assay and cell
growth by cell counting. The CC50 (50% cell cytotoxicity)
for each drug was determined.
Tyrphostin treatment of BM5 (LP-BM5 chronically
infected) cells
BM5 cells (5 3 105/flask) were treated with different
doses of tyrphostins (0–50 mM) for 48 h at 37°C and
quivalent volumes of DMSO were added to untreated
ontrol cells. Reverse transcriptase (RT) activity was
easured in the virus particles isolated from the culture
edium as previously described (Goff et al., 1981). Cells
ere harvested and cellular proteins were extracted with
IPA buffer (50 mM Tris–HCl, pH 7.5, 0.5 M NaHPO4, 0.5%
P-40, 0.25% Na-deoxycholate, 0.1% SDS) (Priel et al.,
991), for further analysis.
cute infection of SC-1 cells with the LP-BM5 virus
ixture and tyrphostin treatment
Culture supernatant (0.1 ml) containing 103 PFU/ml of
P-BM5 MuLV virus mixture was used for infecting 5 3
05/flask SC-1 cells, treated with Polybrene (8 mg/ml), in
the presence or absence of 10 mM AG-1387. Seven days
after infection the culture medium was collected and
virus was pelleted as described above. The cells were
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101MAIDS INHIBITION BY TYRPHOSTIN DERIVATIVEharvested and cellular proteins were extracted by RIPA
buffer.
Detection of the viral gag proteins
Equal amounts of cellular proteins or total amounts of
pelleted virus (lysed by 0.03% NP-40 at 37°C for 30 min)
from tyrphostin-treated and untreated cells were ana-
lyzed by Western blot analysis (Towbin et al., 1979), using
pecific anti-p15 or anti-p30 MuLV antibodies that also
ecognize the MAIDS viral pr60gag protein (received from
D. G. Blair, NCI, FCRDC, NIH, Frederick, MD). The blot
was developed using the Western blot detection re-
agents and enhanced chemiluminescence (ECL; Amer-
sham, Arlington Heights, IL).
Infection of C57BL/6J mice with MAIDS virus and
treatment with tyrphostin
Mice (3 weeks old) were inoculated intraperitoneally
with 103 PFU/ml of LP-BM5 virus mixture. Single or sev-
ral injections of tyrphostin AG-1387 (5 mg/kg) were
dministered intraperitoneally at different times after vi-
us injection (see Results). Mice were terminated 10
onths after virus inoculation. Spleens and lymph nodes
ere removed, weighed, and subjected to histopatho-
ogic examination, and the spleen cells were dispersed
or further analysis.
-cell response to Con A
Con A assays were performed on the dispersed
pleen cells as previously described (Huang et al., 1992;
imard and Jolicoeur, 1991), except that 5 3 105 cells
ere used in each well and the response to Con A (1
mg/ml) was assayed. Experiments were conducted in
quadruplets.
Viral RNA analysis in spleens from infected and
tyrphostin-treated mice
Total RNA was extracted from spleen cells derived
from both virus-infected and uninfected mice treated and
untreated with tyrphostins using the Tri-reagent kit (Mo-
lecular Research Center, Cincinnati, OH). Equal amounts
of RNA were analyzed by Northern blot using the D30
probe (Huang et al., 1989, 1992).
Histopathology
Spleens removed from the different mice groups were
fixed with 10% Formalin sectioned at 5 mm and stained
with hematoxylin and eosin for light microscopy exami-
nation.
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